Groundbreaking Technologies Fueling Novel Diagnostic & Precision Medicine Strategies, 2020 - ResearchAndMarkets.com

DUBLIN--()--The "Groundbreaking Technologies Fueling Novel Diagnostic and Precision Medicine Strategies" report has been added to ResearchAndMarkets.com's offering.

This edition of the Life Science, Health & Wellness TechVision Opportunity Engine (TOE) comprises groundbreaking advances across breast cancer screening, next generation sequencing, proteomics, and digital health platforms. The TOE also provides insights across innovative immunotherapy and precision medicine strategies.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Key Topics Covered:

Recent Innovations in Life Sciences, Health & Wellness

  • Artificial Intelligence Enabling Breast Cancer Screening
  • Advancing Next-generation Sequencing Technologies
  • Leveraging Proteomics for Health and Disease Studies
  • Targeted Therapy for Managing Cardiovascular Risks
  • Digital Tools for Neurological Disorders
  • Smart Gait Analysis System for Accurately Identify the Mobility Disorders
  • Repurposing Drugs for Delaying Age-related Disorders
  • Disease Analysis and Identification Through MS Platform
  • Gut Microbiota-based Prevention of Type-2 Diabetes
  • Unique Oligosaccharide Binding Protein Platform as Immunotherapy
  • Antibodies Therapeutics for Emerging Severe Pathologies
  • AI-powered Drug Disease Matching Platform
  • Highly Selective MET Kinase Inhibitors as Oncotherapy
  • Artificial Intelligence Empowering Drug Screening
  • Digital Cell Biology through Optofluidic Technology
  • Pain Relief through Wireless Nerve Stimulation
  • AI-driven Stroke Care Synchronization
  • Massive Digital Data Storage and Computation
  • Targeting CD73 to Solve Glioblastoma Tumor Resistance
  • Identifying the Key to Effective Immunotherapy
  • Novel Drug for Treatment of Epitheloid Sarcoma
  • FcRn As a Drug Target for IgG Autoimmune Disorders
  • Lumasiran Delivers in Phase 3 Clinical Study
  • Novel Drug for the Treatment of Small Cell Lung Cancer
  • Innovative Needle-free Blood Draw Device
  • BCMA-targeting Antibody-Drug Conjugate

Industry Influencers

  • Key Contacts
  • Your F&S Thought Leader

For more information about this report visit https://www.researchandmarkets.com/r/zcmows

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900